Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity

Oleksandr Yagensky(Max Planck Institute for Biophysical Chemistry), Mahdokht Kohansal-Nodehi(Max Planck Institute for Biophysical Chemistry), Saravanan Gunaseelan(National University of Singapore), Tamara Rabe(Max Planck Institute for Biophysical Chemistry), Saima Zafar(German Center for Neurodegenerative Diseases), Inga Zerr(German Center for Neurodegenerative Diseases), Wolfgang Härtig(Leipzig University), Henning Urlaub(Universitätsmedizin Göttingen), John Jia En Chua(Agency for Science, Technology and Research)
eLife
August 27, 2019
Cited by 42Open Access
Full Text

Abstract

Alzheimer's disease is the most prevalent neurodegenerative disorder leading to progressive cognitive decline. Despite decades of research, understanding AD progression at the molecular level, especially at its early stages, remains elusive. Here, we identified several presymptomatic AD markers by investigating brain proteome changes over the course of neurodegeneration in a transgenic mouse model of AD (3×Tg-AD). We show that one of these markers, heme-binding protein 1 (Hebp1), is elevated in the brains of both 3×Tg-AD mice and patients affected by rapidly-progressing forms of AD. Hebp1, predominantly expressed in neurons, interacts with the mitochondrial contact site complex (MICOS) and exhibits a perimitochondrial localization. Strikingly, wildtype, but not Hebp1-deficient, neurons showed elevated cytotoxicity in response to heme-induced apoptosis. Increased survivability in Hebp1-deficient neurons is conferred by blocking the activation of the mitochondrial-associated caspase signaling pathway. Taken together, our data highlight a role of Hebp1 in progressive neuronal loss during AD progression.


Related Papers

No related papers found

Powered by citation graph analysis